Ascletis Says China Accepts IND Filing for Novel NASH Treatment
publication date: Feb 18, 2020
Ascletis Pharma, a Hangzhou antiviral company, has filed an IND with China's NMPA for ASC41, a self-developed Category 1 treatment for NASH. Ascletis expects to combine ASC41 with ASC40, another novel Ascletis product, in trials. ASC41 is an oral thyroid hormone receptor beta (THR-beta) agonist, while ASC40 is an oral fatty acid synthase (FASN) inhibitor. In 2018, Ascletis' Ganovo®, an innovative t NS3/4A protease treatment for hepatitis C, was approved for China use, the first approved direct-acting anti-viral agent developed by a China company. More details....
Stock Symbol: (HK: 1672)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.